EQRx Archives | Arboretum Ventures

EQRx

EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position

EQRx, Inc. (Nasdaq: EQRX), recently announced plans to reset its business and reported financial results…

Arboretum_JDMay 8, 2023

EQRx News Page

EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress

Arboretum_JDFebruary 23, 2023

EQRx News Page

EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency

Application is based on data from the pivotal Phase 3 AENEAS trial evaluating aumolertinib as…

Arboretum_JDDecember 2, 2022

EQRx News Page

EQRx Reports Second Quarter 2022 Financial Results and Recent Corporate Progress

EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative…

Arboretum_JDAugust 11, 2022

EQRx News Page

EQRx Announces Acceptance of Market Authorization Application by the UK’s MHRA

EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative…

Arboretum_JDJune 14, 2022

EQRx News Page

EQRx Announces New Data for Lead Oncology Programs

EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative…

Arboretum_JDMay 27, 2022

EQRx News Page

EQRx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Progress

EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative…

Arboretum_JDMarch 23, 2022

EQRx News Page

EQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results

EQRx, Inc. (Nasdaq: EQRX) a new type of pharmaceutical company committed to developing and delivering…

Casey FrushourJanuary 18, 2022

EQRx News Page

EQRx Enters Memorandum of Understanding with CVS Health to Create Cost Savings and Improve Patient Access to Innovative Medicines

EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering…

Casey FrushourJanuary 10, 2022

EQRx Home Page News Page

EQRx Debuts as Publicly Traded Company

CM Life Sciences III (Nasdaq: CMLT, CMLTW, CMLTU), a life science-focused special purpose acquisition company,…

Arboretum_JDDecember 17, 2021

EQRx

EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position

EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress

EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency

EQRx Reports Second Quarter 2022 Financial Results and Recent Corporate Progress

EQRx Announces Acceptance of Market Authorization Application by the UK’s MHRA

EQRx Announces New Data for Lead Oncology Programs

EQRx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Progress

EQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results

EQRx Enters Memorandum of Understanding with CVS Health to Create Cost Savings and Improve Patient Access to Innovative Medicines

EQRx Debuts as Publicly Traded Company

News & Insights

ARCHIVES